ReviewFrontiers in physiology2026
Lipid-derived microbial metabolites at the gut-liver interface: regulation of intestinal barrier function, immune signaling, and metabolic inflammation.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid-derived and lipid-related microbial metabolites form a functional interface between the gut microbiota, intestinal barrier integrity, mucosal immunity, hepatic metabolism, and systemic immunometabolic homeostasis. At the gut-liver axis, these molecules should not be regarded as passive end-products of microbial metabolism, but as compartment-sensitive signals whose biological effects depend on site of production, mucosal exposure, epithelial utilization, portal delivery, hepatic handling, receptor distribution, and inflammatory context. This narrative review examines five major metabolite classes: short-chain fatty acids, including branched-chain fatty acids; microbially transformed bile acids; bacterial sphingolipids; PUFA-derived or microbially modulated lipid mediators; and choline-, carnitine-, and phospholipid-derived co-metabolites such as trimethylamine N-oxide. We discuss how these pathways regulate tight-junction architecture, epithelial energy metabolism, mucus-associated defense, antimicrobial programs, innate and adaptive immune-cell signaling, bile-acid receptor networks, and portal inflammatory exposure. The evidence is most mature for classical short-chain fatty acids and bile-acid signaling, emerging but mechanistically compelling for bacterial sphingolipids and PUFA-derived mediators, context-dependent for TMAO, and still limited for aging-specific and sarcopenia-related extrapolations. Across classes, translation is constrained by incomplete causal inference, preclinical predominance, heterogeneous human evidence, inconsistent metabolomic and lipidomic standardization, and the non-equivalence of fecal concentrations, mucosal exposure, portal delivery, and systemic availability. Future studies should move beyond single-metabolite associations toward longitudinal, multi-compartment, mechanism-informed models integrating targeted metabolomics/lipidomics, permeability markers, immune phenotyping, liver and cardiometabolic endpoints, and functional outcomes relevant to frailty and sarcopenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.